Y-mAbs' longtime CEO steps down abruptly as FDA reviews second pediatric cancer drug
Over the past seven years, Claus Moller helped steer Y-mAbs Therapeutics from a secretive Danish biotech startup laser-focused on two pediatric cancer treatments to a Nasdaq-listed company boasting a three-pronged platform of immunotherapies, radiotherapies and companion diagnostics.
But as Y-mAbs gets deeper into commercialization, its longtime CEO is heading out.
Founder Thomas Gad — whose daughter’s diagnosis of neuroblastoma inspired the company’s creation by an ex-Genmab crew — will step in as interim CEO while Y-mAbs searches for Moller’s permanent successor.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.